

INTRODUCTION

The Problem: Post-surgical infections require immediate, high-dose, localized antibiotic treatment without the risk of device migration.

The Solution (Figure 1): An interconnected microparticle array ("bead-on-a-string") that anchors to the wound bed, conforms to tissue, and enables highly controlled release and monitoring.

Objective: Evaluate polymer matrices to identify a structurally stable formulation capable of sustained, high-capacity localized delivery of Rifampin at 37° C.




Figure 1: Clinical deployment of the retrievable array in a C-section wound bed. The interconnected depots prevent migration, providing sustained localized analgesia with an instant mechanical retrieval failsafe.

METHODS

Standardized Depots: Custom V2 3D-printed open-face molds created identical 125 μ L interconnected microparticle arrays spanning a central 0.5 mm thread trench.

Matrix Fabrication: Evaluated architectures included:

- Physical Hydrogels:** 10% (w/v) uncrosslinked Gelatin.
- Composite Barriers:** PLGA dip-coated Gelatin and freeze-thawed PVA cores.
- Structural Shells:** Solvent-cast, vacuum-evaporated hollow PLGA.
- Synthetic Networks:** PPODA-QT crosslinked via Michael addition (Pre-loaded vs. Solvent-swelled post-loading).

Release Protocol: In vitro Rifampin release testing in PBS at 37° C. A strict "Complete Media Replacement" methodology was utilized to maintain sink conditions. Release kinetics were evaluated by comparing the absolute cumulative mass (mg) of Rifampin delivered.



Figure 2: Custom 3D-printed V2 casting molds (125 μ L cavity) featuring a central trench to accommodate the surgical thread backbone.

RESULTS

Phase 1 & 2: Physical Instability & Barrier Failure

- Uncrosslinked 10% gelatin failed at 37° C, undergoing rapid macroscopic degradation within 2 hours.
- Attempting to bottleneck release via a PLGA dip-coating yielded failure modes: Gelatin cores absorbed PBS and physically fractured the PLGA shell.
- (See Burst Phase Inset):** While PLGA-coated PVA and Hollow PLGA shells maintained structural integrity, they exhibited rapid dose-dumping, plateauing entirely within the first 2 hours of deployment.

Phase 3: Synthetic Stability & Sustained Delivery

- Transitioning to synthetic PPODA-QT networks yielded structurally stable matrices at 37° C.
- Pre-loaded PPODA-QT:** Direct mixing of Rifampin prior to casting severely stunted total release (<0.1 mg over 144 hrs), indicating the complex drug likely scavenged the thiol-acrylate crosslinking reaction.
- Post-loaded PPODA-QT:** Swelling blank matrices in a highly concentrated solvent bath proved highly successful. (See Master Graph): This method prevented crosslinking interference, yielding a sustained, gradual diffusion profile delivering a significantly higher payload (~0.75 mg) over a 6-day period.




Figure 3: Fabricated matrix iterations: (A) PLGA-coated Gelatin, (B) PLGA-coated PVA, (C) Pre-loaded PPODA-QT, (D) Hollow PLGA Shells, and (E) Post-loaded PPODA-QT.




Figure 4: In vitro structural stability of the evaluated interconnected microparticle arrays (Vials A-E) in PBS at 37° C, highlighting the structural failure of physical hydrogels (A) versus the stability of the optimized synthetic network (E).




Figure 5: Comparative cumulative mass delivery from standardized 125 μ L depots over 144 hours. Solvent-swelled PPODA-QT demonstrated superior loading capacity and sustained diffusion compared to boundary coatings and hollow shells.

RESULTS




Figure 6: The 4-hour burst phase inset clearly highlights the rapid initial dose-dumping of the PLGA-coated architectures prior to their premature plateau.

SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS

- The physical manufacturability of an interconnected microparticle array was successfully validated.
- Uncrosslinked physical hydrogels (gelatin) and thin dip-coatings fail to provide the thermal stability or diffusion bottleneck required for sustained physiological implants.
- Post-loading structurally stable synthetic networks (PPODA-QT) via solvent-swelling successfully prevents crosslinking interference and provides the necessary sustained release profile.

REFERENCES

- Lee, Y. J., & Kim, M. S. (2025). Biomedicine & Pharmacotherapy Advances in drug-loaded microspheres for targeted, controlled, and sustained drug delivery: Potential, applications, and future directions. *Biomedicine & Pharmacotherapy*, 189, 118244. <https://doi.org/10.1016/j.biopha.2025.118244>
- Ali, S., Ranjha, N. M., Ahmad, B., Khan, A. A., Hassan, F. U., Aziz, T., Alharbi, M., Alshammari, A., Alasmari, A. F., & Esa, M. (2023). Sustained Release of Drug Facilitated Through Chemically Crosslinked Polyvinyl Alcohol-Gelatin (PVA-GE) Hydrogels. *A sustainable biomedical approach*, 25(2), 56-65.
- Zhao, Z., Dong, P., Wang, H., Su, J., Yu, M., Gao, T., Zhang, Q., Chen, W., Yang, J., & Zhang, H. (2025). Hydrogel-Based Microspheres for Intra-Articular Osteoarthritis Therapy: Multifunctional Carriers for Drug Delivery and Cartilage Repair: A Comprehensive Review Hydrogel-Based Microspheres for Intra-Articular Osteoarthritis Therapy: Multifunctional Carriers for Drug Delivery and Cartilage Repair: A Comprehensive Review. 9114. <https://doi.org/10.2147/IJN.S538490>
- Parikh, K. S., Anders, N. M., Omiadze, R., Josyula, A., Shi, R., He, P., Yazdi, Y., McDonnell, P. J., Hanes, J., & Ensign, L. M. (2021). Ultra-thin, high strength, antibiotic-eluting sutures for prevention of ophthalmic infection. *August 2020*, 1-12. <https://doi.org/10.1002/btm2.10204>

ACKNOWLEDGEMENTS

Thanks to Dr. Brent Vernon and Dr. Chandrashekhar Pathak for their invaluable mentorship, collaboration, and guidance throughout this project.